COL10A1 is a potential immunotherapy biomarker associated with immune infiltration and deficient mismatch repair in colon cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 73(1), 17–48 (2023).
  MedlineGoogle Scholar
• 3. Morgan E, Arnold M, Gini A et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2), 338–344 (2023).
  MedlineGoogle Scholar
• 4. Ganesh K, Stadler ZK, Cercek A et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16(6), 361–375 (2019).
  MedlineGoogle Scholar
• 5. Diaz LA Jr, Le DT. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 373(20), 1979 (2015).
  MedlineGoogle Scholar
• 6. Smith KM, Desai J. Nivolumab for the treatment of colorectal cancer. Expert Rev. Anticancer. Ther. 18(7), 611–618 (2018).
  Medline CASGoogle Scholar
• 7. Romero D. New first-line therapy for dMMR/MSI-H CRC. Nat. Rev. Clin. Oncol. 18(2), 63 (2021). • Summary of the clinical trials that showed colorectal cancer (CRC) patients with deficient mismatch repair/microsatellite instability-high tumors benefiting from immune-checkpoint inhibition therapy.
  MedlineGoogle Scholar
• 8. Overman MJ, Mcdermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18(9), 1182–1191 (2017).
  Medline CASGoogle Scholar
• 9. Overman MJ, Lonardi S, Wong KYM et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36(8), 773–779 (2018).
  Medline CASGoogle Scholar
• 10. Schrock AB, Ouyang C, Sandhu J et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann. Oncol. 30(7), 1096–1103 (2019).
  Medline CASGoogle Scholar
• 11. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960–1964 (2006).
  Medline CASGoogle Scholar
• 12. Le DT, Durham JN, Smith KN et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017).
  Medline CASGoogle Scholar
• 13. Kielty CM, Kwan AP, Holmes DF, Schor SL, Grant ME. Type X collagen, a product of hypertrophic chondrocytes. Biochem. J. 227(2), 545–554 (1985).
  Medline CASGoogle Scholar
• 14. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196(4), 395–406 (2012).
  Medline CASGoogle Scholar
• 15. Chen S, Wei Y, Liu H et al. Analysis of collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics. Bioengineered 12(1), 127–137 (2021).
  Medline CASGoogle Scholar
• 16. Zhou W, Li Y, Gu D et al. High expression COL10A1 promotes breast cancer progression and predicts poor prognosis. Heliyon 8(10), e11083 (2022).
  Medline CASGoogle Scholar
• 17. Liang Y, Xia W, Zhang T et al. Upregulated collagen COL10A1 remodels the extracellular matrix and promotes malignant progression in lung adenocarcinoma. Front. Oncol. 10, 573534 (2020).
  MedlineGoogle Scholar
• 18. Huang H, Li T, Ye G et al. High expression of COL10A1 is associated with poor prognosis in colorectal cancer. Onco Targets Ther. 11, 1571–1581 (2018). • Evidence of COL10A1 in the tumorigenesis and disease progression of CRC with underlying mechanisms involving epithelial–mesenchymal transition.
  MedlineGoogle Scholar
• 19. Kahlert UD, Shi W, Strecker M et al. COL10A1 allows stratification of invasiveness of colon cancer and associates to extracellular matrix and immune cell enrichment in the tumor parenchyma. Front. Oncol. 12, 1007514 (2022). •• Addresses the immunological role of COL10A1 in CRC.
  Medline CASGoogle Scholar
• 20. Bonneville R, Krook MA, Kautto EA et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis. Oncol. 2017, doi: 10.1200/PO.17.00073 (2017).
  MedlineGoogle Scholar
• 21. Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4), 782–795 (2013).
  Medline CASGoogle Scholar
• 22. Charoentong P, Finotello F, Angelova M et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18(1), 248–262 (2017).
  Medline CASGoogle Scholar
• 23. Xu L, Deng C, Pang B et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 78(23), 6575–6580 (2018).
  Medline CASGoogle Scholar
• 24. Yoshihara K, Shahmoradgoli M, Martínez E et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
  MedlineGoogle Scholar
• 25. Wang X, Bai Y, Zhang F et al. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: a comprehensive study based on bioinformatics and clinical analysis validation. Front. Immunol. 14, 955949 (2023).
  Medline CASGoogle Scholar
• 26. Mao X, Xu J, Wang W et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer 20(1), 131 (2021).
  Medline CASGoogle Scholar
• 27. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 141(1), 39–51 (2010).
  Medline CASGoogle Scholar
• 28. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 35(5), 585–600 (2013).
  Medline CASGoogle Scholar
• 29. Hu W, Li X, Zhang C, Yang Y, Jiang J, Wu C. Tumor-associated macrophages in cancers. Clin. Transl. Oncol. 18(3), 251–258 (2016).
  Medline CASGoogle Scholar
• 30. Laoui D, Van Overmeire E, Movahedi K et al. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology 216(11), 1192–1202 (2011).
  Medline CASGoogle Scholar
• 31. Schouppe E, De Baetselier P, Van Ginderachter JA, Sarukhan A. Instruction of myeloid cells by the tumor microenvironment: open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Oncoimmunology 1(7), 1135–1145 (2012).
  MedlineGoogle Scholar
• 32. Mclean MH, Murray GI, Stewart KN et al. The inflammatory microenvironment in colorectal neoplasia. PLOS ONE 6(1), e15366 (2011).
  Medline CASGoogle Scholar
• 33. Chen K, Liu Q, Tsang LL et al. Human MSCs promotes colorectal cancer epithelial–mesenchymal transition and progression via CCL5/β-catenin/Slug pathway. Cell Death Dis. 8(5), e2819 (2017).
  Medline CASGoogle Scholar
• 34. Chun E, Lavoie S, Michaud M et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 12(2), 244–257 (2015).
  Medline CASGoogle Scholar
• 35. Sasaki S, Baba T, Shinagawa K, Matsushima K, Mukaida N. Crucial involvement of the CCL3–CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice. Int. J. Cancer 135(6), 1297–1306 (2014).
  Medline CASGoogle Scholar
• 36. Fisher RC, Bellamkonda K, Alex Molina L et al. Disrupting inflammation-associated CXCL8–CXCR1 signaling inhibits tumorigenicity initiated by sporadic- and colitis-colon cancer stem cells. Neoplasia 21(3), 269–281 (2019).
  Medline CASGoogle Scholar
• 37. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).
  MedlineGoogle Scholar
• 38. Liu Q, Yang C, Wang S et al. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression. Cell Commun. Signal. 18(1), 51 (2020).
  Medline CASGoogle Scholar
• 39. Wei C, Yang C, Wang S et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol. Cancer 18(1), 64 (2019).
  MedlineGoogle Scholar
• 40. Cristescu R, Mogg R, Ayers M et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362(6411), eaar3593 (2018).
  MedlineGoogle Scholar
• 41. Sharma P, Siddiqui BA, Anandhan S et al. The next decade of immune checkpoint therapy. Cancer Discov. 11(4), 838–857 (2021). •• Discussions of the current understanding of resistance mechanisms in immune checkpoint therapy and suggestions of patient selection and rational combination therapy to improve efficacy and minimize toxicities.
  Medline CASGoogle Scholar
• 42. Lenz HJ, Van Cutsem E, Luisa Limon M et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J. Clin. Oncol. 40(2), 161–170 (2022).
  Medline CASGoogle Scholar
• 43. Cohen R, Bennouna J, Meurisse A et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J. Immunother. Cancer 8(2), e001499 (2020).
  MedlineGoogle Scholar
• 44. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 45. Le DT, Kim TW, Van Cutsem E et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol. 38(1), 11–19 (2020).
  Medline CASGoogle Scholar
• 46. Dolcetti R, Viel A, Doglioni C et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol. 154(6), 1805–1813 (1999).
  Medline CASGoogle Scholar
• 47. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91(12), 2417–2422 (2001).
  Medline CASGoogle Scholar
• 48. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J. Transl. Med. 5, 62 (2007).
  MedlineGoogle Scholar